Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 39 - Medicinal preparations containing antigens or antibodies
Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
10/2000
10/25/2000EP1045688A1 Lipomatrix preparation
10/25/2000EP0750626B1 Corpuscles of stannius protein, stanniocalcin
10/25/2000CN1271389A Nucleic acid vaccines encoding G protein of respiratory syncytial virus
10/25/2000CN1270839A Antigenic antibody vaccine of foot-and-mouth disease
10/25/2000CN1270838A Adjuvant used in vaccine
10/25/2000CN1057774C 乙型肝炎疫苗 Hepatitis B Vaccine
10/24/2000US6136957 Antibodies which bind granulocyte-macrophane colony-stimulating factor receptor
10/24/2000US6136606 Kit for preparing an inoculant which prevents viral infection
10/24/2000US6136585 Attenuation of negative stranded RNA viruses by rearrangement of genes and uses thereof
10/24/2000US6136570 Method for producing RNA viruses from cDNA
10/24/2000US6136561 Methods of preparing carboxy-terminally truncated recombinant flavivirus envelope glycoproteins employing drosophila melanogaster expression systems
10/24/2000US6136560 Amidotransferase, ratB, of streptococcus pneumoniae
10/24/2000US6136556 TCTS response regulator
10/24/2000US6136528 Multiple sclerosis virus
10/24/2000US6136527 Polypeptides derived from proteins of the hepatitis C virus, test kits containing these polypeptides and vaccines against infections of hepatitis C viruses
10/24/2000US6136325 Live vaccine constituting minor risk for humans
10/24/2000US6136324 Deactivating tuberculosis gene
10/24/2000US6136323 Forming immunology response
10/24/2000US6136322 Genetic engineering
10/24/2000US6136321 Incubation in a polysorbate
10/24/2000US6136320 Orally acceptable immunogenic composition
10/24/2000US6136319 Method of treating viral diseases in animals
10/24/2000US6136318 Genetic engineering
10/24/2000US6136315 Compositions and methods using complexes of heat shock protein 70 and antigenic molecules for the treatment and prevention of neoplastic diseases
10/24/2000US6136313 Processes and intermediates for synthetic antibody derivatives
10/24/2000US6136312 Method for producing an IgM preparation for intravenous application
10/24/2000US6136310 Recombinant anti-CD4 antibodies for human therapy
10/24/2000US6136306 Treatment of a mammalian patient having a tumor by administering to the patient allogenic donor lymphocytes that have been co-cultured in the presence of the patient-derived lymphocytes under conditions sufficient to alloactivate the
10/24/2000CA2139664C Covalent polar lipid-peptide conjugates for biological targeting
10/20/2000CA2271451A1 Variant c-terminal fragment of plasmodium falciparum msp-1
10/19/2000WO2000062071A1 Diagnostic and therapeutic use of antibodies against the urokinase receptor
10/19/2000WO2000062067A1 Novel transduction molecules and methods for using same
10/19/2000WO2000062063A1 Methods for the diagnosis and treatment of metastatic prostate tumors
10/19/2000WO2000061813A1 A second mammalian tankyrase
10/19/2000WO2000061779A1 49 human secreted proteins
10/19/2000WO2000061772A2 Compositions and methods for generating an immune response utilizing alphavirus-based vector systems
10/19/2000WO2000061766A2 Telomerase-specific cancer vaccine
10/19/2000WO2000061762A1 RECOMBINANT TOXIN A/TOXIN B VACCINE AGAINST $i(CLOSTRIDIUM DIFFICILE)
10/19/2000WO2000061761A2 Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines
10/19/2000WO2000061758A1 Viral variants
10/19/2000WO2000061757A1 Tumor necrosis factor homologs and nucleic acids encoding the same
10/19/2000WO2000061756A2 Compounds for immunotherapy and diagnosis of breast cancer and methods for their use
10/19/2000WO2000061754A2 Human proteins and polynucleotides encoding them
10/19/2000WO2000061753A2 Compositions and methods for the treatment and diagnosis of breast cancer
10/19/2000WO2000061747A2 Clasp-2 transmembrane proteins
10/19/2000WO2000061746A1 13 transmembrane protein expressed in prostate cancer
10/19/2000WO2000061739A1 Method for controlling the activity of immunologically functional molecule
10/19/2000WO2000061737A2 Production of attenuated negative stranded rna virus vaccines
10/19/2000WO2000061736A2 Recombinant and mutant marek's disease virus
10/19/2000WO2000061724A2 Anti-bacterial vaccine compositions
10/19/2000WO2000061637A1 Erythropoietin receptor antibodies
10/19/2000WO2000061635A2 Method for the stabilization of chimeric immunoglobulins or immunoglobulin fragments, and stabilized anti-egp-2 scfv fragment
10/19/2000WO2000061628A1 49 human secreted proteins
10/19/2000WO2000061627A1 49 human secreted proteins
10/19/2000WO2000061622A2 Genes associated with diseases of the kidney
10/19/2000WO2000061621A2 Flea head, nerve cord, hindgut and malpighian tubule nucleic acid molecules, proteins and uses thereof
10/19/2000WO2000061620A1 49 human secreted proteins
10/19/2000WO2000061613A2 Channel forming toxins as antiviral agents
10/19/2000WO2000061612A2 Compounds and methods for therapy and diagnosis of lung cancer
10/19/2000WO2000061611A2 Production of attenuated chimeric respiratory syncytial virus vaccines from cloned nucleotide sequences
10/19/2000WO2000061610A2 Prostate-restricted gene 30p3c8 expressed in prostate cancer
10/19/2000WO2000061543A2 Esters of l-carnitine or alkanoyl l-carnitines
10/19/2000WO2000061185A1 Docetaxel in combination with rhumab her2 for the treatment of cancers
10/19/2000WO2000061184A2 Dry formulation for transcutaneous immunization
10/19/2000WO2000061183A2 Verotoxin treatment of lymphomas
10/19/2000WO2000061181A1 USE OF mCRP TO ENHANCE IMMUNE RESPONSES
10/19/2000WO2000061171A2 Uses of mammalian ox2 protein and related reagents
10/19/2000WO2000061165A1 Conserved adhesin motif and methods of use thereof
10/19/2000WO2000061157A1 Methods for skewing the balance between th1 and th2 immune responses
10/19/2000WO2000061151A2 Oligodeoxynucleotide and its use to induce an immune response
10/19/2000WO2000061145A1 Methods of inducing cancer cell death and tumor regression
10/19/2000WO2000061132A1 Compositions containing immunotoxins and agents that inhibit dendritic cell maturation for inducing immune tolerance to a graft
10/19/2000WO2000061069A2 Methods and compositions for use in the treatment of hyperlipidemia
10/19/2000WO2000061067A2 Anti-hiv 1 vaccine comprising the entire or part of the tat hiv-1 protein
10/19/2000WO2000038711A3 Purification of polysaccharide-protein conjugate vaccines by ultrafiltration with ammonium sulfate solutions
10/19/2000WO2000035484A3 Methods and compositions for decreasing allergic reactions to surface allergens
10/19/2000WO2000034780A3 METHODS AND COMPOSITIONS USEFUL FOR TARGETING ACTIVATED VITRONECTIN RECEPTOR αvβ¿3?
10/19/2000WO2000034308A3 Protein transduction system and methods of use thereof
10/19/2000WO2000033872A3 Method of and compositions for immunization with the pseudomonas v antigen
10/19/2000WO2000032769A3 Mage-10 or mage-8 derived hla-a2.1-binding oligopeptides
10/19/2000WO2000032626A8 Methods of using epitope peptides of human pathogens
10/19/2000WO2000013702A9 Use of an angiogenic factor for the treatment of microvascular angiopathies
10/19/2000DE19917195A1 New peptide derived from the MUC-1 tumor marker, used to induce a cytotoxic T cell response for treatment or prevention of tumors
10/19/2000DE19915057A1 Monoklonale Antikörper gegen das humane Mcm3 Protein, Verfahren zu ihrer Herstellung und ihre Verwendung Monoclonal antibodies to human protein Mcm3, processes for their preparation and their use
10/19/2000CA2815763A1 Anti-bacterial vaccine compositions
10/19/2000CA2760534A1 Compositions and methods for generating an immune response utilizing alphavirus-based vector systems
10/19/2000CA2704600A1 A method for producing antibodies with increased adcc activity
10/19/2000CA2382628A1 Compositions containing immunotoxins and agents that inhibit dendritic cell maturation for inducing immune tolerance to a graft
10/19/2000CA2372028A1 Flea head, nerve cord, hindgut and malpighian tubule nucleic acid molecules, proteins and uses thereof
10/19/2000CA2371223A1 49 human secreted proteins
10/19/2000CA2370767A1 49 human secreted proteins
10/19/2000CA2370563A1 Anti-hiv 1 vaccine comprising the entire or part of the tat hiv-1 protein
10/19/2000CA2370523A1 49 human secreted proteins
10/19/2000CA2370237A1 Methods for the diagnosis and treatment of metastatic prostate tumors
10/19/2000CA2369817A1 Production of attenuated negative stranded rna virus vaccines from cloned nucleotide sequences
10/19/2000CA2369578A1 Compounds and methods for therapy and diagnosis of lung cancer
10/19/2000CA2369454A1 Uses of mammalian ox2 protein and related reagents
10/19/2000CA2369413A1 Transmembrane protein expressed in prostate and other cancers
10/19/2000CA2369384A1 Prostate-restricted gene 30p3c8 expressed in prostate cancer
10/19/2000CA2369200A1 Production of attenuated chimeric respiratory syncytial virus vaccines from cloned nucleotide sequences
1 ... 1452 1453 1454 1455 1456 1457 1458 1459 1460 1461 1462 1463 1464 1465 1466 1467 1468 1469 1470 1471 1472 ... 1823